REPVOG 0.3/10 (Repaglinide (1mg) + Voglibose (0.3mg))

Repvog 0.3/10 Tablet is a formulation that combines two therapeutic agents aimed at managing type 2 diabetes mellitus. This medication assists in regulating elevated blood glucose levels after meals. It is recommended for patients who have not achieved adequate glycemic control with other medications and dietary measures. The administration of Repvog 0.3/10 Tablet is advised to occur immediately following meals. The prescribing physician will determine the appropriate dosage tailored to the patient’s specific needs. It is crucial not to discontinue use without the healthcare provider’s guidance, as abrupt cessation may lead to an increase in blood sugar levels, heightening the risk for severe complications such as renal impairment and vision loss. In the event of a missed dose, patients should refrain from taking the tablet between meals; instead, they should wait until the next meal and resume standard dosing thereafter. A double dose should never be taken to compensate for a missed one. This medication is meant to be part of a broader treatment regimen that includes a balanced diet, consistent physical activity, and weight management as recommended by the healthcare professional. Monitoring blood glucose levels regularly is essential during treatment. Patients should notify their doctor of any pre-existing kidney or liver conditions, urinary tract infections, or if they are using diuretics. Pregnant and lactating individuals are also advised to seek medical counsel prior to using this medication. It is advisable to limit alcohol consumption while on this treatment, as it could elevate the likelihood of experiencing certain adverse effects.